Why the study?
Heart failure and type 2 diabetes share pathogenesis, risk factors, and medications, requiring an updated summary of their interaction and treatments to inform clinical practice.
This review highlights the efficacy of novel medications like SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone in managing the comorbidity of type 2 diabetes and heart failure.
Answers are grounded in this paper and cite their sources.
May guide comorbidity management in T2D; leaves open comparative effectiveness and sequencing trials.
Both heart failure and type 2 diabetes are prevalent conditions and share similar pathogenesis, risk factors, and treatment medications. This review aims to inform clinical practice by summarizing the interaction between heart failure and type 2 diabetes, as well as the medications used to manage them. Novel medications such as Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-likepeptide-1 receptor agonists, and finerenone have been shown to protect patients with type 2 diabetes from hospitalization for heart failure. SGLT2 inhibitors have also proven effective in patients with heart failure, regardless of the presence of type 2 diabetes. When choosing diabetes treatment medications for patients with heart failure and type 2 diabetes, shared decision-making can be helpful in weighing the benefits and harms based on individual scenarios. The selection of guideline-directed medical therapy aligns with patients without type 2 diabetes. Given the rapid evolution of knowledge in this field, clinicians need to stay updated with the latest evidence to provide optimal medical care.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: